Literature DB >> 24502891

Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study.

Cem Celik1, Nicel Tasdemir2, Remzi Abali2, Ercan Bastu3, Murat Yilmaz4.   

Abstract

OBJECTIVE: To investigate whether retesting with the oral glucose tolerance test (OGTT) is useful and necessary for all women with polycystic ovary syndrome (PCOS).
DESIGN: Follow-up study.
SETTING: Tertiary medical center. PATIENT(S): Eighty-four women with PCOS and 45 healthy controls. INTERVENTION(S): Peripheral venous blood sampling. MAIN OUTCOME MEASURE(S): We performed a 75-g 2-hour OGTT in women with normal glucose tolerance (NGT) and impaired glucose tolerance (IGT) at the time of the first test with and without PCOS. RESULT(S): The average follow-up period for women with PCOS was 2.6 years (range, 2-4.17 years). Seventy-eight of these women had NGT at baseline, 11.5% converted to IGT, with an annualized incidence rate of 4.5%. Of those women with IGT at baseline (n = 6), 33.3% converted to type 2 diabetes mellitus, with an annualized incidence rate of 10.4%. In the healthy subjects, the average follow-up period was 2.6 years (range, 2-4.08 years). Forty-two of these women had NGT at baseline, 2.3% converted to IGT, giving a progression of 0.9% per year. Among the three women with IGT at baseline, 33.3% reverted to NGT, and 66.6% had persistent IGT. CONCLUSION(S): Conversion rates from NGT to IGT or type 2 diabetes mellitus were accelerated in women with PCOS compared with healthy subjects. Women with PCOS should be tested regularly for early detection of abnormal glucose tolerance. In addition, the interval for periodic rescreening should be determined by further studies involving more women with PCOS.
Copyright © 2014 American Society for Reproductive Medicine. All rights reserved.

Entities:  

Keywords:  Follow-up; diabetes mellitus; impaired glucose tolerance; polycystic ovary syndrome

Mesh:

Year:  2014        PMID: 24502891     DOI: 10.1016/j.fertnstert.2013.12.050

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  20 in total

Review 1.  Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

Authors:  Lara C Morley; Thomas Tang; Ephia Yasmin; Robert J Norman; Adam H Balen
Journal:  Cochrane Database Syst Rev       Date:  2017-11-29

2.  History of infertility and risk of type 2 diabetes mellitus: a prospective cohort study.

Authors:  Deirdre K Tobias; Audrey J Gaskins; Stacey A Missmer; Frank B Hu; JoAnn E Manson; Germaine M Buck Louis; Cuilin Zhang; Jorge E Chavarro
Journal:  Diabetologia       Date:  2015-01-18       Impact factor: 10.122

Review 3.  Associations Between Asthma and Polycystic Ovary Syndrome: Current Perspectives.

Authors:  Yue Xu; Zhi-Yang Zhou; Jie-Xue Pan; He-Feng Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-05       Impact factor: 6.055

4.  Risk of type 2 diabetes mellitus in polycystic ovary syndrome is associated with obesity: a meta-analysis of observational studies.

Authors:  Panagiotis Anagnostis; Rodis D Paparodis; Julia K Bosdou; Christina Bothou; Djuro Macut; Dimitrios G Goulis; Sarantis Livadas
Journal:  Endocrine       Date:  2021-06-26       Impact factor: 3.633

5.  Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus-a prospective, population-based cohort study.

Authors:  M M Ollila; S West; S Keinänen-Kiukaanniemi; J Jokelainen; J Auvinen; K Puukka; A Ruokonen; M-R Järvelin; J S Tapanainen; S Franks; T T Piltonen; L C Morin-Papunen
Journal:  Hum Reprod       Date:  2016-12-28       Impact factor: 6.918

6.  Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome.

Authors:  U Ezeh; M D Pisarska; R Azziz
Journal:  Hum Reprod       Date:  2022-03-01       Impact factor: 6.918

7.  Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome.

Authors:  Abigail Sharpe; Lara C Morley; Thomas Tang; Robert J Norman; Adam H Balen
Journal:  Cochrane Database Syst Rev       Date:  2019-12-17

Review 8.  Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women.

Authors:  Dinka Pavicic Baldani; Lana Skrgatic; Roya Ougouag
Journal:  Int J Endocrinol       Date:  2015-06-01       Impact factor: 3.257

9.  Physical Properties of Blood Are Altered in Young and Lean Women with Polycystic Ovary Syndrome.

Authors:  Michael J Simmonds; Nikki Milne; Kee Ong; Emily Brotherton; Antony P McNamee; Jarod Horobin; Surendran Sabapathy
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

10.  Polycystic ovary syndrome: aggressive or protective factor for the retina? Evaluation of macular thickness and retinal nerve fiber layers using high-definition optical coherence tomography.

Authors:  José Edvan de Souza-Júnior; Carlos Alexandre de Amorim Garcia; Elvira Maria Mafaldo Soares; Técia Maria Oliveira Maranhão; Telma Maria Araújo Moura Lemos; George Dantas Azevedo
Journal:  J Ophthalmol       Date:  2015-02-11       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.